Zurich Cantonal Bank
NMRA icon

Zurich Cantonal Bank’s Neumora Therapeutics NMRA Stock Holding History

Zurich Cantonal Bank’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-27,008
Closed -$286K – 2668
2024
Q4 		$286K Buy
+27,008
New +$324K ﹤0.01% 1972

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $120M AUM 72.64% 1-Year Est. Return

Zurich Cantonal Bank's NMRA Position: Q1 2025 in Review

Zurich Cantonal Bank sold out of Neumora Therapeutics (NMRA) in Q1 2025, closing a stake of 27,008 shares — an estimated $286K sold.

Zurich Cantonal Bank first reported a position in NMRA in Q4 2024 and held it in 1 quarter. The position peaked at $286K in Q4 2024. 115 funds tracked by Wall St. Rank hold NMRA as of Q1 2025.

  • Zurich Cantonal Bank reported no remaining Neumora Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Zurich Cantonal Bank sold 27,008 Neumora Therapeutics shares in Q1 2025, an estimated $286K.
  • Zurich Cantonal Bank first reported a position in Neumora Therapeutics in Q4 2024 and held it in 1 quarter.
  • Zurich Cantonal Bank's Neumora Therapeutics position peaked at $286K in Q4 2024.
  • 115 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2025.

Based on Zurich Cantonal Bank's 13F filing for Q1 2025, filed 7 May 2025.